Cells of the myelomonocytic series, which arise from a single stem cell, express surface antigens that are either unique to granulocytes or monocytes or are shared with cells of other hematopoietic lineages (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . mAbs have been used as powerful means for the identification of these antigens. Some mAbs react with antigens present only during specific early stages of myelomonocytic differentiation, while others identify more differentiated lineage-specific plasma membrane antigens (2-4, 6, 7) . mAbs have also been developed that identify proteins that constitute several leukocyte plasma membrane receptors for fragments of the third component of complement (8, 9) . Since the same ligand is commonly recognized by more than one class of leukocytes, such antibodies typically identify all leukocytes that express the receptor for that particular ligand . For example, mAbs OKM1, OKM 10, and IB4 identify the polypeptide complex comprising the human leukocyte receptor for C3bi (CR3) found on both neutrophils and monocytes (8, 9) . However, recent reports have described the production of mAbs that immunoprecipitate proteins similar to those of the CR3 but that are found uniquely on human neutrophils (10, 11) . These findings suggested the possibility that receptors whose ligand specificity is identical may exhibit antigenic and structural differences between the various classes of leukocytes .
In studies reported here, we set out to identify plasma membrane proteins of human neutrophils that carry antigenic determinants unique to this cell type. To increase the likelihood of producing mAbs to such neutrophil-specific antigens, we used a modification of a novel immunization procedure. Mice were first tolerized to common leukocyte antigens and then immunized with neutrophils.
(HT) medium, and 20 d later supernatants were tested by IFA for antibodies reactive with PMN. Selected positive colonies were expanded and cloned in 0 .55% soft agar (FMC Corp ., Marine Colloids Division, Rockland, ME) in DME with 20% HIFCS and 13% Iscove's supplement and P/S using chick embryo fibroblasts as a feeder layer. Clone BH2.22.11 was selected because its supernatant selectively stained neutrophils in IFA. This clone was subcloned once, and subclone BH2-C6 was expanded for further use. Ascites was produced by injecting i.p . 10' hybridoma cells into pristane-primed (2,5,10,16-tetramethyl pentadecane; Sigma Chemical Co .) BALB/c mice .
Purification of BH2-C6 . Globulin fraction of ascites was precipitated at 45% saturation of (NH4)2SO 4. Dialyzed precipitate was passed over a column of CM-Affi Gel Blue (Bio Rad Laboratories, Richmond, CA) equilibrated with PBS. BH2-C6 was contained in the flow-through peak .
Iodination of Antibodies. mAb BH2-C6 was iodinated by the chloramine T method (22) using carrier-free [1211 )Na (Amersham Corp ., Arlington Heights, IL). The iodinated antibody was separated from free iodine by chromatography on coarse Sephadex G-25 (Pharmacia Fine Chemicals), dialyzed against PBS, and stored at -20°C. The specific activity of ' 25 I-BH2-C6 was 5-10 ACi/ug protein.
Radioimmunoassay (RIA). Purified PMN were seeded in 96-well flat-bottomed plates at 5 x 104 cells per well . The cells were fixed for 2 h in 1 % formaldehyde in HBSS, washed, and blocked for 1 h with 1% HIFCS in HBSS (HBSS-HIFCS) . The plates were placed on ice, and dilutions of '25 1-BH2-C6 antibody in HBSS-HIFCS were added in triplicate to the wells. For the determination of nonspecific binding, parallel triplicate wells received the same dilutions of '25 I-BH2-C6 containing 20 ug/well cold BH2-C6 . After 1 h, the wells were washed, the cell-associated radioactivity was solubilized with 0.1 % NP-40, and transferred to counting tubes with Q-tips . The data were analyzed using a one-sided, computer-generated, nonlinear regression .
Immunodiffusion. Immunodiffusion was performed using a commercial double immunodiffusion plate (CooperBiomedical, Inc., Malvern, PA).
Gel Electrophoresis . SDS-PAGE of Igs and cellular proteins was performed using standard methods (23) . Purified cells were first treated with i mM diisopropylfluorophosphate (DFP ; Sigma Chemical Co .) (24) , washed in PBS, and lysed on ice in 1% NP-40 buffered with 10 mM Tris-HCI, pH 7.2, containing 0.9% NaCl, 0.25% sodium deoxycholate, 5 mM iodoacetamide, 1 mM PMSF, and 100 U/ml aprotonin (all from Sigma Chemical Co .) . The nuclei were removed by centrifugation for 1 min at 8,000 g, the lysates were adjusted to 1 % SDS and 1 % 2-ME, boiled for 2 min, and the proteins were electrophoresed on 4-11 % gradient gels .
Immunoblotting. Proteins were transferred electrophoretically from SDS-PAGE gels onto nitrocellulose as described elsewhere (25) . A blot from one set of gel lanes was stained with 0 .1 % amido black. Duplicate blots were treated with 5% wt/vol nonfat dry milk (Carnation Co., Los Angeles, CA) dissolved in PBS (BLOTTO) (26) . The blots were incubated overnight on a shaker at 5°C with ' 25 I-BH2-C6 . Typically, 10' TCA-precipitable cpm were added in 80 ml BLOTTO . Blots were washed three times for 30 min in BLOTTO, rinsed in PBS, dried, and exposed to Kodak X-Omat x-ray film at -70°C.
Attachment of Opsonized Sheep E. E were opsonized with C3bi (EIgMC3bi) or IgG (EIgG) as described (27, 28) . 5 x 104 purified human PMN in HBSS were allowed to adhere per 12-mm glass coverslip for 15 min at 37°C. The coverslips were placed on ice and the cells incubated for 30 min in 25 ILI HBSS containing 2 .5,ug of BSA or mAbs in the presence or absence of 2 mg/ml soybean trypsin inhibitor (SBTI, Sigma Chemical Co .). 2.5 x 106 of EIgMC3bi or EIgG were added in 25 ul HBSS to each coverslip. After incubation for 1 h at 37°C, nonbound E were removed by dipping the coverslips into HBSS, and the cells were fixed in 2% glutaraldehyde in HBSS . The binding was enumerated by counting cells in several fields with a x 100 objective in a phase-contrast microscope . Indirect Fluorescence Assay (IFA). Hybridoma supernatant screening was done on buffy coat cells or purified PMN adhered to Terasaki plates (Falcon Labware) . All other assays were done with cells seeded onto 12-mm glass coverslips (Bellco Glass, Inc., Vineland, NJ) . For IFA on buffy coat and HL-60 cells, the coverslips were pretreated for 30 min at RT with 50 jAg/ml poly-r.-lysine (PLL; Sigma Chemical Co.). The cells were incubated with hybridoma culture supernatants or dilutions of primary antibody in HBSS-HIFCS for 45 min at 2°C . Nonbound antibodies were washed off by dipping the coverslips into ice-cold PBS-HIFCS . The cells were fixed in freshly prepared 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA) in PBS . Affinity-purified rhodaminated goat anti-mouse IgM (TRITC-G anti-M IgM, u chain-specific ; CooperBiomedical, Inc.) second antibody was added for 30 min on ice . The cells were photographed on Tri-X film (Kodak Inc ., Rochester, NY) in a Zeiss Standard microscope equipped with phase contrast and epifluorescence optics .
Flow Cytometry . Cells were incubated for I h on ice with 1 ug/ml BH2-C6 in HBSS-HIFBS, washed by centrifugation in HBSS-HIFCS, and incubated for 30 min on ice with a 1 :40 dilution of affinity-purified IgG fraction of goat anti-mouse Ig conjugated with FITC (FITC-G anti-M Ig; CooperBiomedical, Inc .). The cells were washed free of unbound antibody, and resuspended in ice-cold PBS-HIFCS . Fluorescence was analyzed in a Becton Dickinson & Co. (Mountain View, CA) FACS IV flow cytometer equipped with a Spectra-Physics 2-W argon-laser. Excitation was at 488.8 nm at an incident power of 300 mW. Fluorescence emission was measured using a 530 nm long-bandpass filter and recorded as the log of relative intensity . Data were analyzed using a Becton Dickinson & Co. Consort 30 computer system . Sorted cells were centrifuged onto glass slides using a cytocentrifuge (Shandon-Eliot, Inc ., Camberlay, England), fixed in methanol, stained with Wright-Giemsa stain, and photographed .
Immunoelectron Microscopy. Human PMN were incubated in suspension on ice for 1 h with 20 ug/ml BH2-C6 in PBS-HIFCS, washed by centrifugation in HBSS-HIFCS, and sequentially incubated on ice with a rabbit anti-mouse Ig (Miles Laboratories Inc., Elkhart, IN) diluted 1 :20 in HBSS-HIFCS and a 1 :10 dilution of 9 nm colloidal gold prepared by the method of Miihlpfordt (29) and derivatized with staphylococcal protein A. After washing, cell pellets were fixed in 2% glutaraldehyde in PBS, postfixed in 1% osmium tetroxide, dehydrated in ethanol, and embedded in Epon. Thin sections were stained in uranyl acetate, and examined on a Phillips 300 TEM .
Results
Preparation and Characterization of the BH2-C6 Antibody. mAb BH2-C6 is an IgM with K light chains, as demonstrated by Ouchterlony immunodiffusion with rabbit antisera specific for mouse y and K chains. Upon complete reduction and analysis by SDS-PAGE, the molecule separates into heavy and light chains of 80 and 27 kD, respectively (data not shown) .
Specificity of the mAb BH2-C6 for Human Peripheral Blood Neutrophils. The reactivity of BH2-C6 with human cells was examined by IFA . Fig . I shows the resulting fluorescence pattern on living human leukocytes stained with 5 kg/ml BH2-C6. Purified neutrophils (Fig. I c) stain in a bright, uniform circular pattern ( Fig. 1 d) . This staining with BH2-C6 is characteristic of >99% of unspread neutrophils . When buffy coat cells were examined, only the neutrophils were found to stain with BH2-C6 (Fig. 1f) . Unstained cells visible in the phase-contrast micrograph of Fig. I e include lymphocytes (arrowheads), monocytes (large arrows), and platelets (small arrow). In the absence of BH2-C6, there is no fluorescent staining ( Fig. 1 b) of purified PMN (Fig. 1 a) . Further, BH2-C6 failed to stain human erythrocytes, foreskin fibroblasts, as well as frozen sections of lymph nodes . mAb BH2-C6 does not react with neutrophils of mice, rats, and macaque monkeys (data not shown) .
BH2-C6 is cytotoxic . Incubation of BH2-C6-coated neutrophils with fresh guinea pig complement at 37°C results in the lysis of >99% of the cells. Lack of Reactivity of B112-C6 with Human Eosinophils. In IFA analysis, we consistently observed that mAb BH2-C6 does not stain eosinophils in the ring pattern characteristic of plasma membrane antigens . However, the presence of an autofluorescent substance in the granules of eosinophils made it difficult to determine, on the basis of IFA, whether these cells express the surface antigen recognized by mAb BH2-C6 . To further investigate the specificity of mAb BH2-C6 for human neutrophils, we used immunogold electron microscopy . Purified PMN in ice-cold HBSS-HIFCS were sequentially reacted with mAb BH2-C6, rabbit anti-mouse Ig, and colloidal gold derivatized with protein A. Fig. 2 , b and c, shows binding of the gold particles around the entire periphery of the neutrophil . By contrast, the plasma membrane of the eosinophil (Fig . 2 c) , identified by the presence of the crystalloids in the granules (arrowheads), has no bound gold particles. Of five eosinophils observed in thin sections, none stained with the BH2-C6-containing gold immunocomplex, while virtually all neutrophils observed were stained.
When observed at higher magnification (Fig . 2d) , the linear deposition of gold on the surface of the neutrophil indicates that the BH2-C6 antigen is uniformly distributed in the plasma membrane of this cell with no apparent clustering or patching. The high density of the deposited gold suggests the presence of a large number of BH2-C6 antigenic sites on the neutrophil plasma membrane . In the absence of BH2-C6, the plasma membrane of neutrophils is completely devoid of the gold particles (Fig . 2 a) .
Identification ofthe Neutrophil Molecule Recognized by BH2-C6. The biochemical nature of the molecule recognized by BH2-C6 was investigated with immunoblotting of PMN proteins separated by SDS-PAGE under reducing conditions . Separated proteins from lysates of 10 7 PMN and mononuclear cells were transferred electrophoretically onto nitrocellulose, and the band containing the epitope recognized by BH2-C6 was detected with 1251-labeled BH2-C6 . (Fig . 4) . Computer-generated nonlinear fit of the data gives an estimate of 19 .5 ng of antibody bound to this number of cells at saturation, corresponding to 214,000 molecules of 1251-BH2-C6 bound per cell .
Effect of mAb BH2-C6 on the Neutrophil Receptor for C3bi (CR3). mAbs reported to be neutrophil specific (10-1 1) have been shown to immunoprecipitate proteins similar to those of the CD 11 /CD 18 complex of leukocyte antigens . These antigens comprise a family of three dimeric proteins, CD1 la/CD18 (also known as LFA-1), CD 1 lb/CD18 (also known as Mac-1 or the C3bi receptor [CR3]), and CD 1 lc/CD18 (also known as p150,95) (8, 9) . Since the BH2-Ag has a molecular weight closely resembling that of CD 11 b and CD 11 c, we tested the ability of the FIGURE 2. Immunoelectron microscopy of human PMN stained with mAb BH2-C6 . Purified PMN were sequentially stained with mAb BH2-C6, rabbit anti-mouse Ig, and protein Aderivatized 9 nM colloidal gold and prepared for electron microscopy as described in Materials and Methods. Control samples were processed in the absence of mAb BH2-C6. C3bi ligand or the CR3 . Therefore, the binding experiments were done in the absence or presence of the serine protease inhibitor SBTI.
The addition of mAb BH2-C6 reduced the attachment index for EIgMC3bi to 2% of the BSA control, but this effect was partially reversed (to 41% of control) by the addition of SBTI (Table I) . By contrast, the addition of the mAb BH2-C6 had no effect on the ability of the PMN to bind EIgG (Table 1) . Control experiments showed that the binding of EIgG was completely inhibited by the presence of the anti-FcR mAb 3G8 (31) , and this inhibition was not reversed by SBTI .
Three possibilities are suggested by these observations : (a) BH2-C6 may bind to CR3; (b) BH2-C6 may bind to a molecule physically associated with CR3 and thus sterically block ligand binding; (c) BH2-C6 may trigger the release of proteolytic enzymes that cleave C3bi or its receptor. The following data rule out the first two possibilities.
BH2-C6 Does Not Recognize Antigens in the CD18 Complex. We examined the expression of BH2-C6 Ag on PMN from a patient congenitally deficient in all 
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Test particles* -SB three members of the CD 18 complex (Wright, S. D., Z. Chad, and L. Kabbash, manuscript in preparation) . mAb IB4 (directed against CD 18, reference 8) stains normal PMN brightly (Fig. 5 a) , but no staining above background is detected on PMN from the patient (Fig. 5 b) . In contrast, the PMN from the patient react normally with BH2-C6 (Fig. 5c ). These data were confirmed by measuring the binding of radioiodinated 1114 and BH2-C6 to purified PMN. recognize any members of the CD18 family and thus does not recognize the CR3 . BH2-C6 Ag Does Not Cocap with CR3. Purified human PMN were sequentially incubated on ice in suspension with the anti-CR3 mAb OKM 1 (9) and FITC-G anti-M IgG. The cells were warmed to 37°C for 5 min to allow the capping of the OKM 1-CR3 complex, cooled to 5'C, and adhered to PLL-coated coverslips at 5'C. The cells were fixed in paraformaldehyde, incubated sequentially with mAb BH2-C6 and TRITC-G anti-M IgM (Ec chain-specific), and photographed . As can be seen in Fig. 6 , the BH2-Ag does not segregate into the OKM1- Marrow. The specificity of mAb BH2-C6 for a plasma membrane antigen unique to human peripheral blood neutrophils prompted us to investigate the expression of this antigen during myelopoiesis . Cytofluorometric analysis of human bone marrow cells was used in conjunction with histochemical staining and differential counting of sorted cells to establish the distribution of BH2-Ag during neutrophilic differentiation. 5 x 106 human bone marrow cells were stained for I h on ice with 1 Ag/ml mAb BH2-C6 and FITC-G anti-M Ig. In all samples examined, the cellular distribution based on light scatter and differential cell counts was characteristic of normal bone marrow. Analysis of fluorescence shows a cell population negative for BH2-C6-mediated fluorescence and two populations of intermediate and high fluorescence intensity (Fig. 7, A and C) . Together, the positive populations contained 65% of the bone marrow cells analyzed . The cells making up these two populations were sorted using fluorescence intensity gating shown in Fig. 7 , A and C. Differential counts were performed on cytocentrifuge preparations of the sorted cells after Wright-Giemsa staining (Table II) . The cells in the brightly fluorescent population (Fig. 7 C, gate 2) have light scatter characteristics of latestage granulocytic precursors and of mature granulocytes (Fig. 7D) . The population of cells characterized by intermediate-intensity fluorescence (Fig. 7A, gate  1 ) has a light-scatter distribution (Fig. 7B) that partially overlaps that of the highintensity population . However, the bone marrow cells gated in panel A include, in addition, a subpopulation whose light-scatter distribution (Fig. 7B) is characteristic of cells in early stages of myelopoiesis (32) . All myeloblasts observed were negative for BH2-Ag. The earliest granulocytic precursors found to be fluorescence-positive for BH2-Ag are the promyelocytes (Table II) . As the cells mature into myelocytes, there is a continued, low level expression of BH2-Ag. During this stage, there occurs a significant increase in BH2-Ag surface expression as evidenced by the division of myelocytes into the intermediate and high fluorescence intensity populations. The high fluorescence intensity population is composed of metamyelocytes, banded, and segmented neutrophils.
Expression ofBH2-Ag on HL-60 Cells During Neutrophilic Differentiation. In an attempt to confirm in vitro the results of bone marrow analysis, we examined the expression of BH2-Ag on the human myeloblastic-promyelocytec cell line HL-60 (13) . This cell line can be induced to further differentiate along the granulocytic lineage by treatment with various pharmacological agents . In the first experiment, we examined the binding of 1251-BH2-C6 to HL-60 cells cultured in the absence or presence of 40 mM DMO (14) or 1 .5 uM c-RA (15) . After an incubation period of 4 d, the cells were seeded in 96-well, flat-bottomed plates pretreated with 50 /Ag/ml PLL to promote equal adherence ofcontrol and induced cells. A saturating dose of 37 ng 125 1-BH2-C6 and 250 ng cold BH2-C6 (see Fig. 4 ) was added to each well for 1 h on ice and the cells were processed as described in Materials and Methods. Parallel cell samples were evaluated for NBT reduction . The results in Table  III show that only 8% of HL-60 cells cultured in RPMI alone are capable of reducing NBT . By contrast, when HL-60 cells are incubated in the presence of c-RA, the percentage of cells reducing NBT increases 3.4-fold. The corresponding increase for cells incubated with DMO is 5.1-fold .
The level of 1251-BH2-C6 binding to HL-60 cells induced with c-RA or DMO is only 20 and 25%, respectively, of that binding to PMN (Table III) . Thus, it was important to establish whether the incubation of HL-60 cells with these agents results in the induction of BH2-Ag expression in a subpopulation of these cells . To address this question, we used indirect immunofluorescence to determine the percentage of BH2-Ag'' HL-60 cells. As shown in Fig . 8 , only very few (<4%) BH2-Ag'' cells are found in an HL-60 cell population that was incubated in RPMI alone (Fig. 8B) . By contrast, 82% of cells induced with DMO (Fig. 8D) and 90% of cells induced with c-RA (Fig. 8F) express the BH2-Ag.
These results show that the treatment with inducers of granulocytic differentiation, DMO or c-RA, stimulates the HL-60 cells to initiate expression of BH2-Ag. The appearance of this antigen correlates well with cellular changes which indicate granulocytic differentiation : alteration of cell morphology (Fig. 8, A, C , and E) and the ability to reduce NBT . In contrast, the exposure of HL-60 cells to TPA, an inducer of monocytic differentiation, failed to evoke the appearance of BH2-Ag (data not shown) .
This report describes an mAb that exhibits specificity for human peripheral blood neutrophils and for several stages of differentiation of these cells. Analysis of cells by immunofluorescence (Fig. 1) clearly shows that the reactivity of mAb BH2-C6 is restricted to PMN. In numerous assays with blood of several donors, BH2-C6 staining of monocytes, lymphocytes, erythrocytes, or platelets was never observed. Furthermore, in analysis by immunoelectron microscopy, we found no BH2-C6-mediated staining of eosinophil plasma membranes under conditions in which all the neutrophils observed showed surface staining (Fig. 2) . The uniform distribution of the gold-containing immune complexes on the plasma membrane of the neutrophils (Fig. 2) correlates well with the uniform pattern of fluorescence that is characteristic of BH2-C6 staining . This finding demonstrates that BH2-Ag is not located in membrane clusters such as those reported for the PMN type 1 complement receptor (33) . Analysis by immunoblotting of total cellular proteins separated from PMN and mononuclear cells under reducing conditions shows that the molecule recognized by mAb BH2-C6 is a single protein of 157 kD. The width of the band seen on autoradiographs (157 ± 12 kD) suggests that BH2-Ag may be heterogeneously glycosylated (Fig. 3) . The lack of binding of 1251-BH2-C6 to proteins of mononuclear cell lysates indicates that monocytes and lymphocytes do not possess intracellular BH2-Ag or other proteins that carry the BH2-C6-specific determinant.
Binding of mAb BH2-C6 to neutrophils significantly reduces attachment of C3bi-coated erythrocytes to these phagocytes, thus suggesting an association of the BH2-C6 Ag with CR3 . We find, however, that the Ag recognized by BH2-C6 is not expressed on CR3 (CDIIb/CD18), nor on the structurally related CDlla/CD18 or CDllc/CD18 molecules . Cells from a patient deficient in all three members of the CD 18 complex react well with BH2-C6 (Fig. 5) . We further observed that the BH2-C6 Ag does not cocap with CR3 (Fig. 6 ), indicating that it is not associated with CR3 in the plasma membrane.
An explanation for the effects of BH2-C6 on CR3 function is suggested by the observation that its inhibitory effects are suppressed by high concentrations of protease inhibitor (Table I) . Thus, BH2-C6 may trigger the release of proteases that cleave C3bi or its receptor. Two of the neutrophil serine proteases, elastase and cathepsin G (37), have been shown by others to convert C3bi to Cad, which is not recognized by CR3 (34) . Stimulation of secretion of endogenous proteases by antibodies to cell surface proteins has also been reported (35, 36) . While the function of BH2-C6 Ag is still obscure, our data suggest that this antigen may function to trigger secretion by PMN. Studies to examine this possibility are currently under way. Several mAbs have been described in recent years that appear to be specific for human granulocytes (10, 11, (39) (40) (41) . Frequently, these mAbs recognize sugar sequences on glycoproteins and glycolipids (10, 39) . One highly antigenic oligosaccharride, lactose-N-fucopentose III (5) is the epitope of the mAb PMN-7C3 (10) and the AHN series of human granulocyte-specific mAbs (40) . Although the exact nature of the epitope recognized by mAb BH2-C6 remains to be defined, we believe that mAb BH2-C6 recognizes a structure distinct from this oligosaccharride . This conclusion is based on the absence of BH2-C6 reactivity with uninduced HL-60 cells and human myeloblasts, both of which express this oligosaccharride antigen (39, 42) . Furthermore, mAb BH2-C6 recognizes a single neutrophil polypeptide, while mAbs AHN 1-4 identify two proteins with identical antigenic determinants (40) .
The BH2-Ag molecule is expressed on the plasma membrane of all the cells committed to neutrophilic differentiation starting with the promyelocyte . In all bone marrow samples analyzed by cytofluorimetry, the myeloblasts were identified only in the fluorescence-negative population . This correlates well with the finding that the human cell line HL-60 is also negative for BH2-Ag. These cells are arrested in the myeloblastic-promyelocytic stage of development but can be induced to further differentiate along granulocytic or monocytic lineages (13, 17) . Upon induction with c-RA or DMO, 60-90% of HL-60 cells attain the morphological, enzymatic, and functional characteristics of myelocytes (15) (16) and this paper) . Based on our finding that the myelocytes in cytofluorimetric analysis fall predominantly into the fluorescent fraction of intermediate intensity, it could be expected that c-RA or DMO-induced HL-60 cells would express relatively low levels of BH2-Ag as compared with mature neutrophils. In fact, exactly this finding was obtained as shown by RIA (Table III) and IFA (Fig. 8) .
It should be noted that the percentage of DMO and c-RA-induced HL-60 cells that express BH2-Ag is significantly greater than the percentage of these cells capable of reducing NBT . This suggests that the expression of BH2-Ag is an earlier indicator of the granulocytic differentiation of these cells than the ability to generate the superoxide anion.
During the myelocytic stage, there is a significant increase in the plasma membrane expression of BH2-Ag. This is shown by the appearance of myelocytes in the high fluorescence intensity fraction of bone marrow cells sorted by cytofluorimetry . This increase, therefore, occurs at the time when the mitotic divisions cease and the cells initiate maturation into segmented neutrophils. At this stage of neutrophilic development, there is also a significant increase in the expression of the plasma membrane receptors for complement (38) , Fc (38) , and chemotactic peptides (43) , all of which are critical for the function of mature neutrophils. The role played by the BH2-Ag in the biology of the human neutrophil is currently being investigated .
Summary
We have used mice selectively tolerized to antigens of human lymphocytes by treatment with cyclophosphamide to raise an mAb, BH2-C6, that reacts with a plasma membrane antigen specific for human neutrophils. This specificity is demonstrated by indirect immunofluorescence microscopy, cytochemical analysis of fluorescence-positive and -negative cell populations separated by flow cytometry, and by the selective, complement-mediated killing of mAb BH2-C6-treated neutrophils. Additional evidence for the neutrophil specificity of mAb BH2-C6 is shown by immunoelectron microscopy, which demonstrates a lack of reactivity with human eosinophils. Immunoblotting of SDS-PAGE-separated proteins of polymorphonuclear leukocytes with ' 251-labeled BH2-C6 identifies protein with an average molecular mass of 157 kD. Binding studies show that, at saturation, neutrophils bind 214,000 molecules of ' 25 I-BH2-C6 per cell .
Addition of mAb BH2-C6 to neutrophils significantly reduces the number of C3bi-opsonized sheep erythrocytes (EIgMC3bi) bound by these cells. This reduction is partly reversed by the presence of soybean trypsin inhibitor (SBTI), indicating that at least one part of this inhibition is due to BH2-C6-stimulated secretion of a serine protease that may affect ligand binding.
Cytochemical analysis of normal human bone marrow cells sorted by cytofluo-rimetry identifies the promyelocyte as the precursor cell that first expresses BH2-Ag on the plasma membrane. Using the leukemic cell line HL-60, we demonstrate that only inducers of granulocytic differentiation, cis-retinoic acid, and dimethyloxazolidine stimulate the expression of BH2-Ag . These results show that the expression of BH2-Ag during myelomonocytic differentiation is a property uniquely possessed by cells committed to the neutrophilic lineage .
